Artiva Biotherapeutics (NASDAQ:ARTV) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright began coverage on shares of Artiva Biotherapeutics (NASDAQ:ARTV) in a research report released on Monday, MarketBeat reports. The brokerage issued a buy rating and a $20.00 price target on the stock.

Separately, Needham & Company LLC reiterated a “buy” rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a research report on Wednesday, November 13th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $21.00.

Artiva Biotherapeutics Price Performance

ARTV stock opened at $10.58 on Monday. The business has a 50 day moving average of $11.41. Artiva Biotherapeutics has a one year low of $9.68 and a one year high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). As a group, equities research analysts forecast that Artiva Biotherapeutics will post -4.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ARTV. BNP Paribas Financial Markets bought a new stake in shares of Artiva Biotherapeutics during the 3rd quarter valued at about $42,000. MetLife Investment Management LLC purchased a new position in Artiva Biotherapeutics during the third quarter valued at $135,000. JPMorgan Chase & Co. bought a new position in shares of Artiva Biotherapeutics in the 3rd quarter worth about $166,000. Barclays PLC bought a new position in shares of Artiva Biotherapeutics during the third quarter valued at approximately $304,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in Artiva Biotherapeutics during the third quarter valued at $623,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.